Abbvie Inc
NYSE:ABBV
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
138.08
203.87
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Abbvie Inc
Abbvie Inc
Additional Paid In Capital
Abbvie Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$21.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Additional Paid In Capital
$7.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$6.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
2%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$12.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
24%
|
CAGR 10-Years
18%
|
|
Abbvie Inc
Glance View
AbbVie Inc. is a global biopharmaceutical company that emerged from Abbott Laboratories in 2013, establishing itself as a key player in the healthcare sector with a strong focus on developing innovative therapies. Headquartered in North Chicago, Illinois, AbbVie specializes in immunology, oncology, neuroscience, and virology, boasting a diverse portfolio of products designed to address complex health challenges. Its flagship drug, Humira, has been a cornerstone of the company’s success, contributing significantly to its revenues since it was launched. However, with the expiration of Humira's patent, AbbVie is strategically transitioning its focus toward new treatments, including promising drugs in late-stage development and an expanding pipeline that aims to harness advanced technologies and unique therapeutic approaches. As an investor, AbbVie presents an intriguing opportunity due to its robust commitment to research and development, evidenced by substantial investments that have bolstered its product lineup. The company’s proactive measures to mitigate potential revenue loss from Humira's generics include the acquisition of Allergan in 2020, which expanded its presence in aesthetic medicine and neurology with successful brands like Botox. This move not only diversified its revenue streams but also solidified AbbVie’s competitive position in the biopharmaceutical landscape. With a commitment to delivering long-term value, strong dividend performance, and a focus on innovation, AbbVie is positioned to adapt and thrive amidst the evolving industry dynamics, making it a compelling consideration for investors seeking growth in the healthcare space.
See Also
What is Abbvie Inc's Additional Paid In Capital?
Additional Paid In Capital
21.2B
USD
Based on the financial report for Sep 30, 2024, Abbvie Inc's Additional Paid In Capital amounts to 21.2B USD.
What is Abbvie Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
18%
Over the last year, the Additional Paid In Capital growth was 6%. The average annual Additional Paid In Capital growth rates for Abbvie Inc have been 5% over the past three years , 7% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
